JP2009535021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535021A5 JP2009535021A5 JP2009506889A JP2009506889A JP2009535021A5 JP 2009535021 A5 JP2009535021 A5 JP 2009535021A5 JP 2009506889 A JP2009506889 A JP 2009506889A JP 2009506889 A JP2009506889 A JP 2009506889A JP 2009535021 A5 JP2009535021 A5 JP 2009535021A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- seq
- identity
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 10
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 102000051965 human ALK Human genes 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79583106P | 2006-04-28 | 2006-04-28 | |
| US60/795,831 | 2006-04-28 | ||
| PCT/CH2007/000202 WO2007124610A1 (en) | 2006-04-28 | 2007-04-27 | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013112192A Division JP5911821B2 (ja) | 2006-04-28 | 2013-05-28 | 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009535021A JP2009535021A (ja) | 2009-10-01 |
| JP2009535021A5 true JP2009535021A5 (https=) | 2011-07-28 |
| JP5431920B2 JP5431920B2 (ja) | 2014-03-05 |
Family
ID=38515389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506889A Expired - Fee Related JP5431920B2 (ja) | 2006-04-28 | 2007-04-27 | 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体 |
| JP2013112192A Active JP5911821B2 (ja) | 2006-04-28 | 2013-05-28 | 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013112192A Active JP5911821B2 (ja) | 2006-04-28 | 2013-05-28 | 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7902340B2 (https=) |
| EP (2) | EP2013236B1 (https=) |
| JP (2) | JP5431920B2 (https=) |
| KR (1) | KR101457228B1 (https=) |
| CN (1) | CN101443361B (https=) |
| AU (1) | AU2007246144B2 (https=) |
| BR (1) | BRPI0710971A2 (https=) |
| CA (1) | CA2650822C (https=) |
| DK (1) | DK2013236T3 (https=) |
| ES (1) | ES2547248T3 (https=) |
| IL (1) | IL194752A0 (https=) |
| MX (1) | MX2008013705A (https=) |
| NZ (1) | NZ572248A (https=) |
| PL (1) | PL2013236T3 (https=) |
| RU (1) | RU2460540C2 (https=) |
| WO (1) | WO2007124610A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710971A2 (pt) * | 2006-04-28 | 2011-05-31 | Esbatech Ag | anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk |
| WO2008131575A2 (en) * | 2007-04-27 | 2008-11-06 | Esbatech Ag | Anti-alk antibodies suitable for treating metastatic cancers or tumors |
| US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| KR102050040B1 (ko) | 2008-06-25 | 2019-11-28 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 저해하는 안정한 가용성 항체 |
| PL2307458T3 (pl) * | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| HK1220465A1 (zh) | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| CN104861069B (zh) * | 2014-02-21 | 2018-12-18 | 无锡傲锐东源生物科技有限公司 | 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途 |
| WO2015184231A2 (en) * | 2014-05-30 | 2015-12-03 | Kolltan Pharmaceuticals, Inc. | Regulators of anaplastic lymphoma kinase and uses thereof |
| US11091559B2 (en) | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| CA2940470C (en) | 2015-09-18 | 2019-08-20 | Signpath Pharma Inc. | Treatment for glioblastoma |
| MY196631A (en) | 2015-10-13 | 2023-04-24 | Eureka Therapeutics Inc | Antibody Agents Specific for Human Cd19 and uses Thereof |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| WO2017147408A1 (en) * | 2016-02-25 | 2017-08-31 | The Regents Of The University Of California | Methods for the treatment of hematologic cancer |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス, インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| JP7654402B2 (ja) * | 2018-02-09 | 2025-04-01 | アクセルロン ファーマ インコーポレイテッド | 異所性骨化を処置するための方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN113960313B (zh) * | 2021-12-22 | 2022-04-12 | 上海思路迪医学检验所有限公司 | 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21505A (en) * | 1858-09-14 | Improvement in bullet-machines | ||
| US6696548B2 (en) * | 1993-12-03 | 2004-02-24 | St. Jude Children's Research Hospital | Antibodies for recognition of alk protein tyrosine/kinase receptor |
| US5529925A (en) | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| WO1998002462A1 (en) | 1996-07-16 | 1998-01-22 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Immunoglobulin superfamily domains and fragments with increased solubility |
| JPH1116250A (ja) * | 1997-06-20 | 1999-01-22 | Pioneer Electron Corp | 情報再生システム |
| ATE273323T1 (de) * | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN |
| CA2412650C (en) | 2000-06-14 | 2011-08-02 | Georgetown University | Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| JP2006508638A (ja) * | 2002-05-22 | 2006-03-16 | エスバテック・アーゲー | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
| US7888485B2 (en) | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| WO2006020684A2 (en) | 2004-08-10 | 2006-02-23 | Institute For Multiple Myeloma And Bone Cancer Research | Methods of regulating differentiation and treating of multiple myeloma |
| BRPI0710971A2 (pt) * | 2006-04-28 | 2011-05-31 | Esbatech Ag | anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk |
-
2007
- 2007-04-27 BR BRPI0710971-7A patent/BRPI0710971A2/pt not_active IP Right Cessation
- 2007-04-27 CN CN200780017546.6A patent/CN101443361B/zh not_active Expired - Fee Related
- 2007-04-27 AU AU2007246144A patent/AU2007246144B2/en not_active Ceased
- 2007-04-27 RU RU2008146922/10A patent/RU2460540C2/ru not_active IP Right Cessation
- 2007-04-27 NZ NZ572248A patent/NZ572248A/en not_active IP Right Cessation
- 2007-04-27 ES ES07720099.6T patent/ES2547248T3/es active Active
- 2007-04-27 EP EP07720099.6A patent/EP2013236B1/en active Active
- 2007-04-27 KR KR1020087026220A patent/KR101457228B1/ko not_active Expired - Fee Related
- 2007-04-27 PL PL07720099T patent/PL2013236T3/pl unknown
- 2007-04-27 US US11/796,549 patent/US7902340B2/en not_active Expired - Fee Related
- 2007-04-27 MX MX2008013705A patent/MX2008013705A/es active IP Right Grant
- 2007-04-27 CA CA2650822A patent/CA2650822C/en not_active Expired - Fee Related
- 2007-04-27 EP EP13000844.4A patent/EP2604627A1/en not_active Withdrawn
- 2007-04-27 DK DK07720099.6T patent/DK2013236T3/en active
- 2007-04-27 JP JP2009506889A patent/JP5431920B2/ja not_active Expired - Fee Related
- 2007-04-27 WO PCT/CH2007/000202 patent/WO2007124610A1/en not_active Ceased
-
2008
- 2008-10-22 IL IL194752A patent/IL194752A0/en active IP Right Grant
-
2011
- 2011-01-31 US US13/017,925 patent/US8945563B2/en not_active Expired - Fee Related
-
2013
- 2013-05-28 JP JP2013112192A patent/JP5911821B2/ja active Active
-
2014
- 2014-12-16 US US14/571,433 patent/US9512411B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535021A5 (https=) | ||
| JP2023509196A5 (https=) | ||
| TWI713942B (zh) | 與集落刺激因子1受體(csf1r)結合之抗體類 | |
| JP2022037133A (ja) | 改良された血清アルブミン結合剤 | |
| JP2020023523A5 (https=) | ||
| RU2008146922A (ru) | Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk) | |
| JP2010535012A5 (https=) | ||
| JP6681433B2 (ja) | P2x7受容体アンタゴニスト及びアゴニスト | |
| JP2020501531A5 (https=) | ||
| CN108473563B (zh) | 改进的tnf结合剂 | |
| JP2010511388A5 (https=) | ||
| JP2011046732A5 (https=) | ||
| JP2016507523A5 (https=) | ||
| JP2019526273A5 (https=) | ||
| JP2015509097A5 (https=) | ||
| JP2019522490A5 (https=) | ||
| JP2017526339A5 (https=) | ||
| JP2012530496A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| PE20141564A1 (es) | Moleculas de union para bcma y cd3 | |
| JP2013519364A5 (https=) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2014526898A5 (https=) | ||
| JP2016538830A5 (https=) | ||
| JP2012034692A5 (https=) |